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†Department of Chemical and Biomolecular Engineering and ‡Department of Bioengineering, University of California, Berkeley, CaliforniaABSTRACT Cellular mechanical properties have emerged as central regulators of many critical cell behaviors, including prolif-
eration, motility, and differentiation. Although investigators have developed numerous techniques to influence these properties
indirectly by engineering the extracellular matrix (ECM), relatively few tools are available to directly engineer the cells them-
selves. Here we present a genetic strategy for obtaining graded, dynamic control over cellular mechanical properties by regu-
lating the expression of mutant mechanotransductive proteins from a single copy of a gene placed under a repressible promoter.
With the use of constitutively active mutants of RhoA GTPase and myosin light chain kinase, we show that varying the expres-
sion level of either protein produces graded changes in stress fiber assembly, traction force generation, cellular stiffness, and
migration speed. Using this approach, we demonstrate that soft ECMs render cells maximally sensitive to changes in RhoA
activity, and that by modulating the ability of cells to engage and contract soft ECMs, we can dynamically control cell spreading,
migration, and matrix remodeling. Thus, in addition to providing quantitative relationships between mechanotransductive
signaling, cellular mechanical properties, and dynamic cell behaviors, this strategy enables us to control the physical interactions
between cells and the ECM and thereby dictate how cells respond to matrix properties.INTRODUCTIONCells physically pull on their surroundings through actomy-
osin contraction, and this force is opposed in part by the
mechanical resistance of the extracellular matrix (ECM)
and neighboring cells. The balance between these mechan-
ical forces is critical for maintaining tissue homeostasis and
proper cell function, and changes in the mechanical proper-
ties of cells and the ECM have been implicated in the
development of cancer and other diseases (1–3). The devel-
opment of techniques to precisely engineer the biophysical
properties of the ECM (e.g., protein micropatterning (4)
and tunable-stiffness gels (5)), has led to the observation
that subtle changes in matrix properties, such as stiffness
and geometry, can act through mechanotransductive
signaling networks to dramatically affect cell behavior
(6,7). On the other side of this force balance, however, there
are relatively few tools to control the mechanobiological
properties of cells independently from the properties of
the matrix in a precise manner. As a result, it has been chal-
lenging to develop a quantitative understanding of how
changes in mechanotransductive signaling translate to
changes in specific cellular mechanical properties, and
how these properties influence cell-ECM interactions.
Clarification of these relationships could significantly
advance both our fundamental understanding of cellular
mechanobiology and our ability to direct cell behavior in
cell and tissue engineering applications.
Most direct manipulations of mechanobiological
signaling have sought to control cytoskeletal assembly and
mechanics by turning specific proteins on or off inSubmitted July 14, 2011, and accepted for publication December 19, 2011.
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0006-3495/12/02/0434/9 $2.00a concerted fashion, e.g., with protein overexpression, phar-
macological inhibitors, or siRNA. These approaches have
been instrumental in identifying key mechanotransductive
proteins, but they do not allow one to explore the effects
of more measured changes in protein activity, such as those
that are likely to be encountered physiologically. Surpris-
ingly, only a handful of studies have modulated the activity
of mechanotransductive proteins in these intermediate ways
in living cells, primarily by varying the concentration of
pharmacological inhibitors of the nonmuscle myosin II acti-
vation pathway (8–12). Such pharmacological agents,
however, suffer from several important drawbacks,
including a small set of available drug targets, a limited
ability to activate rather than suppress those targets, rela-
tively steep dose-response relationships, and concerns about
off-target and toxic effects.
In this study, we sought to gain more precise and versatile
control over the mechanobiological properties of cells by
using genetic engineering techniques to vary the expression
of mutant mechanotransductive proteins from a repressible
promoter. We demonstrate that with a single copy of a
constitutively active (CA) mutant gene placed under
a tetracycline-repressible promoter, we can directly modu-
late a number of cellular mechanobiological properties,
including cytoskeletal architecture, cortical stiffness,
traction force generation, and motility, in a graded fashion.
We also show that we can exert dynamic control over
cell-ECM interactions on a collagen hydrogel by reversibly
switching expression of the CA mutants on and off over
time. By enabling graded control over protein activity and
cellular force generation without the disadvantages of
pharmacological inhibitors, this approach can both facil-
itate quantitative investigations of mechanotransductivedoi: 10.1016/j.bpj.2011.12.048
Genetic Control of Cell Mechanobiology 435signaling pathways and serve as a design handle for genet-
ically instructing cell behavior at cell-material interfaces.MATERIALS AND METHODS
Cell lines and reagents
Myc-tagged RhoA Q63L and MLCK ED785-786KK (13) were subcloned
into the retroviral vector CLGPIT containing the tetracycline-repressible
promoter, puromycin resistance, and green fluorescent protein (GFP) as
previously described (14). Viral particles were packaged in 293T cells and
used to infect U373-MG and U87-MG human glioma cells at a multiplicity
of infection of 1 IU/cell. Cells were cultured in Dulbecco’s modified Eagle’s
medium with 10% calf serum, selected with 1 mg/ml puromycin, and
expanded in culturewith 100 ng/ml tetracycline.At least 2 days before exper-
iments were conducted, the culture mediumwas changed to 0.1% calf serum
and the appropriate tetracycline concentration. The U373-MG GFP and
control cell lines were created in the same manner with a single copy of
GFP placed under the tetracycline-repressible promoter and no encoded
gene, respectively. Blebbistatin and oleoyl-L-a-lysophosphatidic acid
were obtained from Sigma-Aldrich (St. Louis,MO), and NSC23766was ob-
tained from EMD Chemicals (Gibbstown, NJ).Western blots
Cellswere lysed inRIPAbufferwith protease andphosphatase inhibitors.Pro-
tein content was measured by BCA assay (Thermo Fisher Scientific, Rock-
ford, IL) and normalized across samples. Lysates were boiled, run on a
4–12% Bis-Tris gel, and transferred onto a PVDF membrane (all from Invi-
trogen, Carlsbad, CA). As the primary antibodies, we used anti-RhoA and
anti-Myc (Cell Signaling Technology, Danvers, MA); anti-glyceraldehyde-
3-phosphate dehydrogenase (anti-GAPDH), anti-vinculin, and anti-myosin
light chain (all Sigma-Aldrich); and anti-integrinb1 and anti-a-actinin (Santa
Cruz Biotechnology, Santa Cruz, CA). HRP-conjugated secondary anti-
bodies (Invitrogen) and enhanced chemiluminescence reagent (Thermo
Fisher Scientific) were used for detection on x-ray film. Bands were quanti-
fiedvia thegel analysis feature in ImageJ andnormalizedbyGAPDHcontent.RhoA activity assay
To measure levels of GTP-bound RhoA, we performed a G-LISA assay
(Cytoskeleton, Denver, CO) according to the manufacturer’s directions.Measurements of GFP fluorescence
An FC-500 flow cytometer (Beckman Coulter, Brea, CA) was used to
measure GFP fluorescence to titer viral particles and to monitor transgene
expression in the U373-MG GFP cell line.Immunofluorescence and phase contrast
microscopy
Epifluorescence and live-cell imaging were performed with a TE2000-E2
microscope (Nikon, Tokyo, Japan). Confocal imaging was performed
with a BX51WI microscope (Olympus, Center Valley, PA) equipped with
swept field confocal technology (Prairie Technologies, Middleton, WI).
Projections of z-stacks were created in ImageJ based on standard deviations
of pixel intensity. For immunofluorescence, we used the following primary
antibodies: anti-focal adhesion kinase pY397 (Invitrogen), anti-N-cadherin
(BD Biosciences, Franklin Lakes, NJ), and anti-vinculin (Sigma-Aldrich).
F-actin and nuclei were stained with phalloidin and 40,6-diamidino-
2-phenylindole, respectively.Traction force microscopy
Fibronectin-coated polyacrylamide gels were synthesized as previously
described (14) from a 5% acrylamide and 0.2% bis-acrylamide (w/v) solu-
tion with yellow-green fluorescent microspheres (0.5 mm diameter) added
before polymerization. We computed maps of cellular traction stresses
from bead positions before and after cell detachment using constrained
Fourier transform traction cytometry (15). We manually drew the cell
outlines and used them to calculate the cell area and shape factor, which
we define as 4  p  (area)/(perimeter)2. We measured the elastic moduli
of the gels for each experiment using atomic force microscopy (AFM).AFM
Using an MFP-3D atomic force microscope (Asylum Research, Santa Bar-
bara, CA), we indented the cells with pyramid-tipped probes (DNP or
OTR4; Bruker AFM Probes, Camarillo, CA) with cantilever spring
constants of 68–129 pN/nm, as measured by thermal calibration. We calcu-
lated the elastic moduli of cells from force curves using a modified Hertz
model (16).Cell migration assays
For scratch wound migration assays, cells were seeded as a monolayer,
scratched with a pipette, and imaged over 6 h. The final change in wound
area was averaged from at least six frames per well. We calculated the
average linear speed from this change in area by dividing by time, dividing
by 2 (because cells migrate inward from two sides), and dividing by the
image height (to convert area/hour to distance/hour). To quantify the
random motility of cells on polyacrylamide and collagen gels, we imaged
the cells every 15 min for 6 h and manually tracked them using ImageJ.
The polyacrylamide gel formulations and stiffness measurements were
made as previously described (14).Collagen gel contraction assay
Cells were suspended in a 1 mg/ml collagen I solution (PureCol; Advanced
BioMatrix, San Diego, CA) at a concentration of 600,000 cells/ml in a mul-
tiwell plate. After 24 h, the gels were detached from the sides of the well.
They were imaged 24 h later, and the change in gel area was quantified with
the use of ImageJ.RESULTS
To provide proof-of-principle that cellular mechanics can be
modulated in a graded fashion through the controlled
expression of mutant mechanotransductive proteins, we first
targeted RhoA GTPase, a strongly validated activator of
actin polymerization and actomyosin contractility (17).
Using retroviral gene delivery, we introduced a Myc-tagged
CA mutant RhoAQ63L under a tetracycline-repressible
promoter into U373-MG human glioblastoma cells, which
are highly motile and mechanosensitive (18,19). We trans-
duced the cells at a low multiplicity of infection so that
each cell would likely receive a single copy of the construct.
To first confirm that we could attenuate the expression of
CA RhoA in a graded fashion by adding varying amounts
of tetracycline to the cell culture medium, we measured
the expression levels of CA RhoA and endogenous RhoA
protein via Western blot. Because the Myc tag on CABiophysical Journal 102(3) 434–442
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FIGURE 1 Graded and dynamic control over mechanotransductive gene expression and protein activity from a tetracycline-repressible promoter.
(a) Western blot showing endogenous RhoA (bottom band of RhoA) and CA RhoA protein levels (Myc-tag and top band of RhoA) in U373-MG control
cells and CA RhoA cells cultured in varying tetracycline concentrations. (b and c) Expression levels of total RhoA (b) and endogenous RhoA (c) were
quantified relative to CA RhoA cells with 100 ng/ml tetracycline (n ¼ 3 blots). (d) Expression levels of Myc-tagged CA RhoA were quantified relative
to CA RhoA cells with no tetracycline (n¼ 4 blots). (e) RhoA activity of U373-MG CA RhoA and control cells measured with a G-LISA assay and displayed
relative to CA RhoA cells with 100 ng/ml tetracycline (n ¼ 3 samples). (f) Fluorescence of U373-MG GFP cells initially cultured in 100 ng/ml tetracycline,
switched to tetracycline-free media, and assayed 0–53 h later. Values are relative to t ¼ 0 (n ¼ 3 samples). For b–f, mean5 SE; *p < 0.05 compared with
100 ng/ml tetracycline or t ¼ 0 (analysis of variance (ANOVA), Tukey post-hoc test).
436 MacKay et al.RhoA adds 1.2 kDa in molecular mass, we were able to
visualize CA RhoA and endogenous RhoA protein as sepa-
rate bands, both recognized by an anti-RhoA antibody
(Fig. 1 a). As expected, CA RhoA expression (top band of
RhoA) was strongest without tetracycline and decreased in
a graded fashion with increasing tetracycline concentration
(Fig. 1, a and b). This top band was completely absent in
control cells transduced with the repressible promoter but
without an encoded transgene. On the other hand, endoge-
nous RhoA expression (bottom band of RhoA) did not
change with tetracycline concentration (Fig. 1, a and c).
With CA RhoA fully expressed (i.e., no tetracycline), we
estimated that CA RhoA constitutes only 18.4 5 0.7% of
the total amount of RhoA protein (n¼ 3 blots), which trans-
lates to a 23% increase in total RhoA protein over endoge-
nous levels. We also used an anti-Myc tag antibody to probe
for CA RhoA alone, which more clearly shows the graded
change in expression with tetracycline concentration
(Fig. 1, a and d). To determine how these changes in CA
RhoA expression translate to changes in overall RhoA
activity, we measured the amount of activated (GTP-bound)
RhoA in cell lysates using an ELISA-based measurement
(Fig. 1 e). Cells cultured with 100 ng/ml tetracycline ex-
hibited a level of RhoA activity similar to that observed in
control cells, and this level increased fivefold as the tetracy-
cline concentration was reduced. This translates to a 14-foldBiophysical Journal 102(3) 434–442increase in RhoA activity over control cells, because the CA
RhoA construct is somewhat leaky even at high tetracycline
concentrations. To investigate the kinetics of transgene
expression, we introduced GFP into U373-MG cells under
the same tetracycline-repressible promoter and tracked the
evolution of fluorescence intensity. After confirming that
the tetracycline dose-activity relationship for GFP was
similar to that observed for CA RhoA (Fig. S1 in the Sup-
porting Material), we switched the GFP expression from
off to on by washing out the tetracycline, and found that
GFP fluorescence was detectable by flow cytometry within
12 h (Fig. 1 f).
Because RhoA is known to reinforce actomyosin stress
fibers, cell-ECM adhesions, and cell-cell adhesions (20),
we investigated whether we could obtain graded control
over the assembly of these structures. Inducing CA RhoA
expression stimulated the formation of stress fibers and
active focal adhesions in a strongly tetracycline-dependent
manner (Fig. 2 a), and treatment with the myosin inhibitor
blebbistatin strongly offset this effect (Fig. S2). We found
that CA RhoA expression did not alter the total protein
levels of integrin b1, vinculin, a-actinin, or myosin
(Fig. S3), suggesting that this RhoA-dependent increase in
active focal adhesions is likely due to changes in the
localization or activation of these proteins, and not to
changes in protein expression. Increasing RhoA activity
100 ng/ml 16 ng/ml 8 ng/ml 4 ng/ml
100 ng/ml 16 ng/ml 8 ng/ml 4 ng/ml
a
b
Tetracycline RhoA activity
pF
A
K
A
ct
in
/ p
FA
K
N
-c
ad
/ D
A
P
I
None
None
FIGURE 2 Graded formation of stress fibers, focal adhesions, and cell-cell contacts with CA RhoA expression. Confocal micrographs of U373-MG CA
RhoA cells cultured in varying tetracycline concentrations before fixation and staining for (a) F-actin (green) and phosphorylated focal adhesion kinase (red
and second panel alone), and (b) N-cadherin (green) and nuclei (blue). The top panel in a is a projection of z-slices. Scale bars ¼ 25 mm.
Genetic Control of Cell Mechanobiology 437also caused cells to adopt a less polarized morphology with
better-defined cell-cell junctions, as evidenced by N-cad-
herin localization (Fig. 2 b). The cytoskeletal architecture
of control cells, on the other hand, was not affected by tetra-
cycline concentration (Fig. S4). To demonstrate graded
control over stress fiber formation in a different cell line,
we introduced tetracycline-repressible CA RhoA into
U87-MG human glioblastoma cells and found similar
effects on stress fiber and focal adhesion density (Fig. S5).
We next sought to determine whether we could use this
control over RhoA activity to modulate the contractile
forces that cells exert on their surroundings. Using traction
force microscopy to map the traction stresses of U373-MG
cells on a flexible polyacrylamide substrate, we found that
the average traction stress of cells increased from 310 Pa
to 510 Pa with increasing CA RhoA expression (Fig. 3 a).
To assess whether we could achieve similar control over
traction force generation through an orthogonal myosin acti-
vation pathway, we created a U373-MG cell linewith a tetra-
cycline-repressible CA mutant of myosin light chain kinase
(MLCK). Although graded activation of MLCK did not alter
stress fiber or focal adhesion formation to the same extent as
CA RhoA (Fig. S6), consistent with previous observations
that MLCK-dependent stress fibers are largely limited to
the cell periphery (21–23), CA MLCK expression did
significantly increase cell-ECM traction forces (Fig. 3 b).
To confirm that this effect was not simply an artifact of tetra-cycline treatment, we measured the traction forces of
U373-MG control cells cultured with or without tetracy-
cline, and found no significant difference (Fig. 3 c). Because
traction stresses are known to be dependent on cell area and
shape (24–27), we measured the area and perimeter of CA
RhoA and CA MLCK cells during traction force experi-
ments. We found that the cell area did not change signifi-
cantly with tetracycline concentration, but the cells did
adopt a less polarized morphology with increasing RhoA/
MLCK activity (Fig. S7).
To demonstrate thatwe could also control intrinsicmechan-
ical properties of the cells, we used AFM nanoindentation to
measure cellular stiffness, which reflects the cell’s shape plas-
ticity and resistance to deformation.We found that increasing
CA RhoA or MLCK expression in the U373-MG cell lines
caused a graded increase in stiffness (Fig. 3 d), which could
be prevented by treatment with blebbistatin (Fig. S8). The
stiffness of control cells, on the other hand, did not increase
with decreasing tetracycline concentration (Fig. 3 d). Plotting
the traction force data (Fig. 3, a and b) against the stiffness
data (Fig. 3 d) shows a strong correlation between traction
force generation and cellular stiffness (Fig. 3, e and f), which
is consistent with previous studies (8,27).
Cellular stiffness, traction force generation, and adhesion
all represent isolated cellular properties that contribute to
more complex cell behaviors that ultimately drive tissue
function. To determine whether our approach could beBiophysical Journal 102(3) 434–442
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FIGURE 3 Graded increases in traction force generation and cortical stiffness with CA RhoA and MLCK expression. Average traction forces of U373-MG
CA RhoA (a), CA MLCK (b), and control cells (c) were measured on polyacrylamide gels with elastic moduli of 8.8 kPa, 12.2 kPa, and 10.3 kPa, respec-
tively. Mean5 SE (n ¼ 50–105 cells per condition); *p < 0.05 compared with 100 ng/ml tetracycline (ANOVA, Tukey post-hoc test). (d) Average cortical
stiffness of U373-MG CA RhoA, CA MLCK, and control cells as measured by AFM. Mean5 SE (n ¼ 350–450 cells per condition); all values are signif-
icantly different from 100 ng/ml tetracycline (p < 0.05 by ANOVA, Tukey post-hoc test). (e and f) Average traction force plotted against stiffness for U373-
MG CA RhoA (e) and CA MLCK cells (f). Pearson’s correlation coefficient for fits ¼ 0.89 and 0.84 for CA RhoA and CA MLCK, respectively.
438 MacKay et al.used to modulate these higher-order behaviors, we focused
on cell migration, which requires both shape plasticity for
a cell to extend its leading edge forward and force genera-
tion to retract its trailing edge. We first performed a scratch
wound migration assay, in which a monolayer of cells is
observed as it migrates into an open space, on the U373.
We found that increasing CA RhoA or MLCK expression
reduced the migration speed of U373-MG cells in a graded
fashion and, as expected, the migration speed of control
cells was not affected by tetracycline concentration (Fig. 4
a). This decrease in migration speed with CA RhoA and
MLCK expression is likely due to the combined effects of
enhanced cell-ECM adhesion, increased intracellular
tension, and stronger cell-cell contacts. To eliminate the
confounding factor of cell-cell contact and to investigate
whether CA RhoA expression alters the relationship
between cell migration speed and ECM stiffness, we tracked
the random migration of single cells on fibronectin-coated
polyacrylamide gels of defined stiffness, ranging from 0.1
to 73 kPa. We found that the average cell migration speed
generally decreased with increasing CA RhoA expression
on all stiffnesses (Fig. 4 b), but the strength of this trend ap-
peared strongest on the softest gels. To clearly portray this
sensitivity to RhoA modulation as a function of ECM stiff-
ness, we calculated the percent decrease in cell speed due to
CA RhoA expression (no tetracycline) as compared with theBiophysical Journal 102(3) 434–442100 ng/ml tetracycline condition for each stiffness. This
analysis revealed that the migration speed of cells is at least
three times more sensitive to RhoA modulation on the two
softer gels than on the three stiffer gels (Fig. 4 c). We also
depicted this result in rosette plots by superimposing the
trajectories of many single cells on each stiffness gel
(Fig. 4 d and Fig. S9). A possible explanation for this depen-
dence of RhoA sensitivity on ECM stiffness is that
decreasing ECM stiffness reduces endogenous RhoA
activity (14), which in turn sensitizes cells on soft ECMs
to CA RhoA expression.
Given the increased sensitivity to RhoA modulation on
soft polyacrylamide gels, we were interested in further
exploring the relationships among RhoA/MLCK activation,
force generation, and migration on another soft, but more
complex and dynamic microenvironment: collagen I hydro-
gels. These hydrogels form fibrillar matrices that cells can
contract and remodel. When U373-MG cells were cultured
on 1 mg/ml collagen gels with the CA genes suppressed, the
cells elongated, bundled the collagen, and used these
bundles as contact guidance cues to migrate toward one
another (Fig. 5 a, Fig. S10, and Movie S1). Increasing CA
RhoA or MLCK expression, however, drastically inhibited
cell spreading and migration (Fig. 5 b and Movie S2).
Higher-magnification time-lapse videos showed that cells
with high RhoA activity remained rounded and attempted
ad
b c
FIGURE 4 Graded decrease in migration speed with CA RhoA and MLCK expression. (a) Average migration speed of U373-MG CA RhoA, CA MLCK,
and control cells during a scratch wound assay (n ¼ 8–13 wells per condition). (b) Average migration speed of U373-MG CA RhoA cells cultured on poly-
acrylamide gels of defined stiffness (n ¼ 150–350 cells per condition). For a and b, mean5 SE; *p < 0.05 compared with 100 ng/ml tetracycline (ANOVA,
Tukey post-hoc test). (c) The percent decrease in migration speed due to CA RhoA expression was calculated from b on each stiffness by subtracting the no-
tetracycline speed from the 100 ng/ml tetracycline speed, and then dividing by the 100 ng/ml tetracycline speed; mean5 SE. (d) Rosette plots depicting
single cell trajectories from b on soft and stiff gels with varying tetracycline concentrations. Axes are in micrometers.
Genetic Control of Cell Mechanobiology 439to engage the collagen matrix through weak, nascent adhe-
sions (Movie S3), whereas cells with low RhoA activity
were able to polarize and generate long-range tractional
forces that facilitated cell migration (Movie S4). We were
able to dynamically and reversibly switch between these
two phenotypes by adding and withdrawing tetracycline
(Fig. 5 c, Movie S5, and Movie S6). Consistent with our
kinetic studies on GFP expression (Fig. 1 f), switching CA
RhoA expression from off to on or vice versa began to alter
cell spreading within 12–18 h. We next investigated our
control over cell behavior in a three-dimensional collagen
hydrogel by encapsulating U373-MG CA RhoA cells during
gelation and measuring the degree to which cells contracted
the gel over a day. We found that increasing CA RhoA
expression reduced cellular contraction of the gel in a graded
fashion almost twofold (Fig. 5 d), which is consistent with
the idea that high RhoA-dependent intracellular contrac-
tility prevents cell spreading and therefore prevents cells
from actively engaging and remodeling the ECM.
Finally, we compared the performance of this approach
with that of analogous pharmacological interventions
commonly used in the field. To our knowledge, no directactivators of RhoA and MLCK are currently available;
therefore, we treated cells with varying concentrations of
two pharmacological agents that should indirectly increase
RhoA activity: lysophosphatidic acid (LPA), which engages
G-protein-coupled receptors upstream of RhoA (28), and
Rac1 inhibitor NSC23766, which would be expected to acti-
vate RhoA through Rho/Rac antagonism (29). To determine
the effects of LPA and NSC23766 on stress fiber formation,
we treated U373-MG control cells with each drug as a single
bolus of defined dosage, and then fixed the cells after 5 min
or 18 h. We found that LPA induced stress fiber formation
within 5 min, but this effect largely dissipated after 18 h
(Fig. S11). This is consistent with previous studies that
showed that the effects of LPA are quite transient (30–32),
presumably due to cellular sequestration and/or degradation
of the drug. In addition, we found that LPA began to precip-
itate out of solution at 10 mM and 50 mM, reflecting its
limited solubility in cell culture medium (33,34). In
contrast, NSC23766 did not appear to significantly alter
actin cytoarchitecture after 5 min, but it did enhance stress
fiber formation and adoption of a less polarized morphology
after 18 h (Fig. S11). During the longer incubation time,Biophysical Journal 102(3) 434–442
60
50
40
30
20
10
0
G
el
 c
on
tra
ct
io
n 
(%
)
1 10 100
Tetracycline (ng/ml)
8
6
4
2
0
S
pe
ed
 (µ
m
/h
r)
1000
Tetracycline (ng/ml)
5 hr 17hr 29hr
41hr 53hr 65hr
100 ng/ml 16 ng/ml 8 ng/ml 4 ng/ml Nonea
b c d
Tetracycline RhoA activity
0
FIGURE 5 Graded and dynamic control over cell behavior on collagen hydrogels. U373-MG CA RhoA cells were cultured on top of 1 mg/ml collagen
hydrogels (a–c) or suspended within them (d). (a) Micrographs of cells cultured on collagen gels with varying tetracycline concentrations. (b) Average migra-
tion speed of cells cultured with or without 100 ng/ml tetracycline. Mean5 SE (n ¼ 120–130 cells per condition); p < 0.001 (Student’s t-test). (c) Frames
fromMovie S5 in which cells were initially cultured without tetracycline and then switched to 100 ng/ml tetracycline at t¼ 0. (d) Percent decrease in gel area
over 24 h during a 3D collagen contraction assay. Mean5 SE (n ¼ 6 wells per condition); all values are significantly different from 100 ng/ml tetracycline
(p < 0.05 by ANOVA, Tukey post-hoc test).
440 MacKay et al.however, the highest concentration of NSC23766 caused
widespread cell death. Incubation time also strongly influ-
enced the effects of these drugs on cellular stiffness:
whereas treatment with LPA or NSC23766 for 5 min signif-
icantly increased the stiffness of control cells, treatment for
18 h did not (Fig. 6, a and b). In addition, when we measured
the migration speed of cells during a scratch wound assay
conducted over 6 h (Fig. 6 c), we found that LPA treatment
did not significantly alter cell migration speed, presumably
because of LPA’s limited period of bioactivity. The higher
concentrations of NSC23766 significantly decreased the6
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FIGURE 6 LPA and NSC23766 transiently increase cellular stiffness and do
U373-MG control cells treated with LPA (a) and NSC23766 (b) at varying conc
migration speed of U373-MG control cells treated with LPA or NSC23766 at vary
condition). Mean5 SE; *p < 0.05 compared with the no-drug condition (ANO
Biophysical Journal 102(3) 434–442cell migration speed, but only at concentrations in which
cell death was observed.DISCUSSION
We have presented a genetic strategy for directly controlling
the mechanobiological properties of living cells by regu-
lating the expression of a single mutant gene from a repress-
ible promoter. Our results show that with relatively low
expression of CA RhoA (only 23% of endogenous RhoA;
Fig. 1 a) or CA MLCK, we were able to induce graded10 100
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not significantly alter cell migration. (a and b) Average cortical stiffness of
entrations for 5 min or 18 h (n ¼ 135–205 cells per condition). (c) Average
ing concentrations during a scratch wound migration assay (n¼ 7 wells per
VA, Tukey post-hoc test).
Genetic Control of Cell Mechanobiology 441changes in stress fiber assembly (Fig. 2 a), cellular force
generation (Fig. 3, a and b), cellular stiffness (Fig. 3 d),
and migration speed (Fig. 4 a and b). We were also able
to reversibly and dynamically control cell-ECM interactions
on soft collagen hydrogels, including cell spreading, migra-
tion, and matrix remodeling (Fig. 5, Movie S1, Movie S2,
Movie S3, Movie S4, Movie S5, and Movie S6). In addition
to providing an important technical innovation, this
approach enables us to gain several new insights into cell-
ECM mechanobiology. First, we show that even though
RhoA/ROCK and MLCK are known to regulate distinct
pools of myosin II (21–23), these signaling systems produce
similarly graded effects on cellular force generation, stiff-
ness, and migration speed, and therefore may overlap signif-
icantly in their function. Second, we find that cells are
maximally sensitive to perturbations in RhoA activity on
soft ECMs (Fig. 4, c and d), presumably because soft
ECMs suppress endogenous RhoA activation. Third, we
directly expose several limitations to pharmacological acti-
vation of RhoAwith LPA and NSC23766, including a short
time window for altering cellular mechanical properties
(<6–18 h; Fig. 6), the poor solubility of LPA in cell culture
medium, and the high toxicity of NSC23766. Because our
genetic approach does not suffer from these drawbacks
and provides access to a wide range of timescales and
protein activities, we envision that it will enable new inves-
tigations and manipulations of dynamic processes that occur
over multiple days, such as stem cell lineage commitment,
multicellular assembly, and matrix remodeling.
In this study, we varied the activity of two different types
of protein (a GTPase and a kinase); however, the tetracy-
cline-repressible construct potentially could be used to
control any type of protein in any cell type. Because our
goal was to obtain precise control over protein activity, we
used retroviral gene delivery to introduce a single copy of
CA RhoA or CA MLCK into cells and thereby limit the
cell-to-cell variability that arises with high multiplicity of
infections or plasmid transfection. A limitation of single-
copy transduction is that protein expression is relatively
low, which may require the expression of CA or dominant
negative mutants to override endogenous feedback inhibi-
tion mechanisms and significantly alter total protein activity.
Alternatively, several modifications could be applied to this
system to increase gene expression. First, cells could be
transduced at a higher multiplicity of infection and subse-
quently sorted by flow cytometry (based on GFP expression)
to isolate cells with the same copy number. Second, the
construct could be adapted for lentiviral gene delivery,
which often yields higher transgene expression than retro-
viral systems. Third, the tetracycline-repressible promoter
could be replaced with a stronger promoter system.
Our ability to vary RhoA and MLCK activity in a contin-
uously graded fashion provides a unique opportunity to
study the quantitative relationships between protein activity
and cellular properties. For example, several studies havesuggested that cell migration speed may depend biphasi-
cally on myosin activation, and that an intermediate level
of activity is optimal for cell migration (10,35,36). We
found that increasing RhoA/MLCK activity led to a graded
decrease in migration speed (Fig. 4), presumably by causing
cells to become too contractile or to adhere too strongly to
the ECM. This leads us to wonder whether reducing
RhoA/MLCK activity below endogenous levels would
also hinder cell migration. With dominant negative or
shRNA constructs, our genetic strategy may enable investi-
gators to explore the effects of graded decreases in RhoA/
MLCK activity and definitively determine whether
a nonlinear relationship between myosin activity and cell
migration actually exists.
Of importance, all of the mechanobiological properties
we measured in this study change in a continuously graded
fashion with graded increases in protein activity, as opposed
to a bimodal (all or nothing) fashion. Because several key
cell behaviors that traditionally have been considered to
lie downstream of mechanotransductive signaling, such as
proliferation and differentiation, are thought to be discrete
endpoints that may be arrived at via a wide degeneracy of
cellular signaling states (37), this in turn raises the question
of howmuch signal activation is sufficient to produce a given
phenotype. The strategy described here should put us in an
excellent position to address these issues, and would be of
particular interest when applied to stem cells and other
developmental systems with a broad palette of phenotypic
plasticity.
Finally, in addition to providing an experimental tool for
investigating how small changes in mechanotransductive
signaling translate to changes in cellular properties and
behavior, our genetic strategy for precisely modulating the
mechanical properties of cells could also serve as a powerful
design handle for directly instructing cell function. We have
shown that by inducing CA RhoA or MLCK expression, we
can directly inhibit cell spreading on a collagen hydrogel
and override physical cues from the matrix that would nor-
mally stimulate cell migration and clustering (Fig. 5 and
Fig. S10). This suggests that cells can be genetically engi-
neered to alter and control their responses to physical
stimuli in their microenvironment, which could be particu-
larly valuable in tissue engineering applications that inter-
face cells with synthetic materials. The ability to precisely
control cellular contractility and migration could also facil-
itate cellular actuation in various biotechnologies, such as
cell-mediated delivery of therapeutics, and in combination
with promoter systems that respond to physiologically rele-
vant molecules (e.g., hormones and steroids), these technol-
ogies could serve a dual role as biosensors. Furthermore, by
introducing specific populations of genetically engineered
cells into animal models and administering transcriptional
inducers or repressors systemically, this genetic approach
could give investigators unique opportunities to study and
control cellular mechanobiology in vivo.Biophysical Journal 102(3) 434–442
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